The collaboration will be led by Bang H. Hoang, M.D., Arnold and Madaleine Penner Professor and Co-Director of Orthopaedic Oncology in the Department of Orthopaedic Surgery at Montefiore Einstein. Dr. Hoang’s research focuses on the pathophysiology and molecular mechanisms of bone and soft tissue cancer, including evaluating the role of NRP2 in pediatric bone cancers such as osteosarcoma.

ATYR2810 has demonstrated anti-tumor effects in multiple preclinical models, including non-small cell lung cancer, triple-negative breast cancer, renal cell carcinoma and glioblastoma. These findings have been presented at scientific conferences, including the American Academy of Cancer Research, and published in a landmark publication in Science Translational Medicine.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.